Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies

Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies

Abstract Aim To assess the efficacy of oral NEPA (netupitant‐palonosetron 300/0.50 mg) over multiple chemotherapy cycles. Methods Two randomized phase III studies evaluated a single dose of oral NEPA given on day 1 in chemotherapy‐naive patients receiving anthracycline‐cyclophosphamide (AC)–based (S...

Full description

Bibliographic Details
Main Authors: Lee Schwartzberg, Meinolf Karthaus, Giorgia Rossi, Giada Rizzi, Maria E. Borroni, Hope S. Rugo, Karin Jordan, Vincent Hansen
Format: Article
Language:English
Published: Wiley 2019-05-01
Series:Cancer Medicine
Subjects:
CINV
delayed phase
efficacy
multiple cycles
NEPA
netupitant
Online Access:https://doi.org/10.1002/cam4.2091

Internet

https://doi.org/10.1002/cam4.2091

Similar Items